Journal: Inflammation

Article Title: IRF7 Modulates Inflammatory Pain Through Upregulating IFNβ in Mice Trigeminal Ganglion

doi: 10.1007/s10753-026-02483-w

Figure Lengend Snippet: Distribution of IRF7-IFNβ signaling in the wild-type TG. ( A , C , E ) Representative images and quantitative co-localization analysis of IRF7, IFNβ or IFNAR co-labeled with neuronal (NeuN), macrophage (CD68), and SGC (GS) markers in the TG (A,C scale bar = 100 μm; E, scale bar = 50 μm).( B , D ) Immunofluorescence images and quantitative co-localization analysis of IRF7 or IFNβ co-labeled with neuronal subtypes expressing CGRP, P2X3R, or NF in the TG (scale bar = 100 μm). ( F ) t-SNE plots showing the distribution of Irf7, Ifnar1, Ifnar2 and the markers of neuronal subtypes in TG neurons, including Calca (encode CGRP), P2rx3 (encode P2X3R) and Nefh (encode NF), based on single-cell sequencing. ( G ) Proportion of Irf7-positive cells co-expressing Nefh, Calca and P2rx3. ( H ) The distribution of Ifnar1 and Ifnar2 in various TG cell types

Article Snippet: The IFNAR1 neutralizing antibody MAR1 or mouse IgG (HY- P99137 and HY-P99977 purchased from MedChem Express LLC) was delivered intra-ganglionically on 3 dpi, at a dose of 1 μL(10 μg/1 μL).

Techniques: Labeling, Immunofluorescence, Expressing, Single Cell, Sequencing

Journal: Inflammation

Article Title: IRF7 Modulates Inflammatory Pain Through Upregulating IFNβ in Mice Trigeminal Ganglion

doi: 10.1007/s10753-026-02483-w

Figure Lengend Snippet: Activation of IFNβ signaling contributes to mechanical nociceptive hypersensitivity in mice. ( A ) Schematic illustration of the experimental procedure of Fig. 5 B and C. ( B ) Mechanical hypersensitivity measured by Von Frey filaments in mice intraperitoneally injected with either PBS or IFNβ (10 4 /10 5 U) on day 3 following CFA injection (N = 6). ( C ) The mechanical pain threshold was assessed daily in CFA injected mice using von Frey test, following treatment with either IFNβ (10⁴ U) or PBS (N = 6). ( D - E ) Mechanical hypersensitivity was evaluated by Von Frey test in mice intra-ganglionic injected with an IFNAR1 antagonist (MAR1) or IgG 3 d post-CFA injection. ( F ) Mechanical hypersensitivity of mice receiving direct injection of IFNβ (20 μL) ( G - H ) Representative images of immunofluorescence staining showing c-Fos (red) in the SpVc of mice treated with PBS or IFNβ (N = 5), or mice receiving intra-ganglionically injection of IgG or MAR1(N = 3). (scale bar = 200 μm). ( I - J ) Quantitative analysis of c-Fos (red) expression in the SpVc among groups. Data are expressed as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001; ( B , E ) using one-way ANOVA followed by post hoc test, while ( C , F , I and J ) using unpaired t test

Article Snippet: The IFNAR1 neutralizing antibody MAR1 or mouse IgG (HY- P99137 and HY-P99977 purchased from MedChem Express LLC) was delivered intra-ganglionically on 3 dpi, at a dose of 1 μL(10 μg/1 μL).

Techniques: Activation Assay, Injection, Immunofluorescence, Staining, Expressing

Journal: Inflammation

Article Title: IRF7 Modulates Inflammatory Pain Through Upregulating IFNβ in Mice Trigeminal Ganglion

doi: 10.1007/s10753-026-02483-w

Figure Lengend Snippet: Effects of IRF7-IFNβ signaling on neuronal sensitization and neuroinflammation. ( A ) Detection of cellular calcium changes over time in neurons stimulated with different concentrations of IFNβ. ( B ) Representative fluorescence images showing the expression of Substance P (SP) in neurons following IFNβ stimulation (scale bar = 40 μm). ( C ) mRNA expression levels of CGRP, P2XR, SP, and TRPV1 in mouse TG neurons stimulated with 100 U or 300 U IFNβ, or pretreated with IgG1κ/MAR1 overnight followed by 100 U IFNβ stimulation. ( D - E ) Representative images and quantitative analysis of GFAP and CD86 in the TG of CFA-treated mice after IFNβ treatment (scale bar = 100 μm). ( F ) Western blot analysis of IRF7, NLRP3, IL6 and GAPDH expression in the TG of mice treated with IFNβ or PBS under inflammatory pain conditions. ( G ) Western blot analysis of IRF7, NLRP3, IL6 and GAPDH expression in the TG of CFA- treated mice intra-ganglionically injected with IgG or an IFNAR1 antagonist. ( H ) Western blot analysis of the expression of IRF7, NLRP3, IL6 and GAPDH in the TG of CFA-injected mice receiving sh-Irf7 or sh-Scr stereotaxic microinjection. Data are expressed as mean ± SD, N = 3-7 mice. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired t test

Article Snippet: The IFNAR1 neutralizing antibody MAR1 or mouse IgG (HY- P99137 and HY-P99977 purchased from MedChem Express LLC) was delivered intra-ganglionically on 3 dpi, at a dose of 1 μL(10 μg/1 μL).

Techniques: Fluorescence, Expressing, Western Blot, Injection, Microinjection

Journal: Cell

Article Title: Serotonin reduction in post-acute sequelae of viral infection

doi: 10.1016/j.cell.2023.09.013

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-mouse IFNAR-1 antibody , Bio X Cell , BE0241; RRID:AB_2687723.

Techniques: Virus, Clinical Proteomics, Recombinant, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Bicinchoninic Acid Protein Assay, SYBR Green Assay, TaqMan Assay, Software, Imaging, Control, Electron Microscopy, Low Protein Binding, Membrane

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment

doi: 10.1007/s00262-021-02864-0

Figure Lengend Snippet: Involvement of type I IFNs in the cytotoxic activity of neutrophils and efficacy of cGAMP treatment. a Bone marrow-derived macrophages (BMDM) were generated in WT and IFNAR1KO mice and expression levels of IFNAR1 on their cell surface by flow cytometer. Gray: isotype control, Red: anti-IFNAR1mAb. b WT- and IFNAR1-BMDM were stimulated with control or IFN-β1 (2000 U/mL) for 24 h and expression levels of H2-Kb on their cell surface by flow cytometer. Gray: isotype control, Blue: control treatment, Red: IFN-β1 treatment. c E0771- or d B16F10-bearing WT, IRF3/IRF7 double knockout (DKO), or interferon (IFN)-alpha receptor 1 knockout (IFNAR1KO) mice received intratumoral injection of PBS or cGAMP (0.5 or 2.0 μg) on day 7. After 4 h of cGAMP treatment, tumor tissues were resected, and TILs were collected for flow cytometric analysis using anti-CD45, anti-CD11b, anti-Ly6C, and anti-Ly6G mAb. The percentages of the increased fraction (CD45+CD11b+Ly6C−Ly6G+ cells) in TILs are depicted. e, f E0771-bearing WT, DKO, or IFNAR1KO mice received intratumoral injection of PBS or cGAMP on day 7. After 4 h of treatment, dLNs were collected and analyzed using the same procedure as in Fig. 3c and d. The proportions of CD4+CD69+ cells in CD4+ T-cells (e) and CD8+CD69+ cells in CD8+ T-cells (f) in dLNs are depicted. B16F10-bearing WT or IFNAR1KO mice (n = 6/group) received intratumoral injections of cGAMP or PBS on day 7. g The tumor area (mm2) and h survival of individual mice were monitored. Statistical significance levels were determined with two-way ANOVA; ns, not significant, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Bars and error bars indicate the mean and SD, respectively (c-f). Statistical significance levels were determined with the unpaired t test; ns, not significant; ****p < 0.0001. Error bars indicate the SD (g). Statistical significance levels were determined with the log-rank (Mantel-Cox) test; ns, not significant; *p < 0.05 (h)

Article Snippet: Splenocytes were collected from WT and IFNAR1KO mice stained with PE-conjugated anti-IFNAR1 mAb (MAR1-5A3) and mouse IgG1,k (MOPC-21), and analyzed by the BD Accuri C6 Plus Flow Cytometer.

Techniques: Activity Assay, Derivative Assay, Generated, Expressing, Flow Cytometry, Control, Double Knockout, Knock-Out, Injection

Journal: Scientific reports

Article Title: Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine.

doi: 10.1038/s41598-018-35755-z

Figure Lengend Snippet: Figure 4. Vaccine protection against challenge in Ifnar1−/− mice. (A–D) Ifnar1−/− mice were immunized with 1010 vp of Ad4-prM-E (n = 9), Ad5-prM-E (n = 10), or sham PBS (n = 10) via the i.m. route according to the timeline in (A). Two experimental replicates were performed. Mice were boosted with the same vaccine and dose at week 3 and then challenged with 106 FFU of mouse-adapted ZIKV strain 41519 at week 7. Weight loss was monitored (B) and mice were sacrificed when a 25% weight loss was reached (C). Asterisks indicate significance in weight compared to PBS sham vaccinated mice as determined by two-way ANOVA (p < 0.05). Survival data was analyzed using a log rank test (***p < 0.001, ****p < 0.0001). Blood was sampled at 4 days post infection (d.p.i) to determine the viral load in the sera using RT-qPCR (D) (**p < 0.01; ****p < 0.0001; one-way ANOVA). To determine immune correlates in Ifnar1−/− mice, groups (n = 5) were immunized with 1010 vp of the indicated Ad vaccine and sacrificed 2 weeks later. Sera was used to determine anti-ZIKV IgG (E) and neutralizing antibodies (F). In addition, an ELISPOT was performed to determine spot-forming cells per million splenocytes against the immunodominant E4–12 epitope (G). ELISA, PRNT50, and ELISPOT are analyzed with one-way ANOVA (**p < 0.01, ****p < 0.0001). Data are expressed as the mean with standard error (SEM).

Article Snippet: C57BL/6 mice were administered 2 mg of anti-mouse Ifnar1 mAb (MAR1-5A3, BioXcell) via the i.p. route one day before ZIKV infection and given 0.5 mg more at day 4 post infection.

Techniques: Infection, Quantitative RT-PCR, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay

Journal: Scientific reports

Article Title: Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine.

doi: 10.1038/s41598-018-35755-z

Figure Lengend Snippet: Figure 5. Vaccine protection against challenge in C57BL/6 mice in anti-Ifnar1 mAb-treated mice. (A–D) C57BL/6 mice (n = 5) were immunized with 1010 vp of Adenovirus vectored vaccine or sham PBS via i.m. injection according to the timeline in (A). Mice were boosted with at week 3 with the indicated vaccine. At week 7, mice were challenged with 106 FFU of mouse-adapted ZIKV strain 41525. One day prior to infection, 2 mg of mouse anti-Ifnar1 was administered via i.p. injection to create a lethal challenge model. Another 0.5 mg of antibody was administered on 4 days post infection (d.p.i). Weight loss was monitored (B) and mice were sacrificed at 25% weight loss (C). Asterisks indicate significant in weight compared to PBS sham vaccinated mice as determined by two-way ANOVA (p < 0.05). Blood was sampled at 4 d.p.i to determine the viral load in the sera using qPCR (D) (****p < 0.0001; one-way ANOVA). Data are expressed as the mean with standard error (SEM).

Article Snippet: C57BL/6 mice were administered 2 mg of anti-mouse Ifnar1 mAb (MAR1-5A3, BioXcell) via the i.p. route one day before ZIKV infection and given 0.5 mg more at day 4 post infection.

Techniques: Injection, Infection